Netzach
Forumer storico
Produzione di reattori di NO
GeNOsys Announces Production of Generators
PROVO, Utah--(BUSINESS WIRE)-- GeNOsys, Inc. (OTCBB: GNYS) today announced the building of the first group of production nitric oxide gas generators. It is anticipated that the generators will be assembled and tested over the next few weeks. The Company plans to place this initial group of generators in research laboratories to facilitate the research of nitric oxide gas in the treatment of a number of conditions and diseases, research that has been very difficult due to the current high cost of nitric oxide gas.
"We are looking forward to placing these units in service in the near future to enable an acceleration of medical research utilizing nitric oxide gas," stated Mr. John W.R. Miller, Chairman of the Board. "Making available systems that will generate nitric oxide gas, on demand and at an affordable cost, will be a valuable tool to researchers."
About GeNOsys:
GeNOsys, Inc. (generated nitric oxide systems) is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems. Nitric oxide gas will be one of the medical gases that will be generated along with various combinations of beneficial medical gases suitable for the control of human disease. Distribution will be accelerated through the use of already existing distribution networks that currently sell related respiratory products. For further information, see the Company's Website at: www.genosysusa.com.
This press release may contain forward-looking statements including the Company's beliefs about its business prospects and future results of operations. These statements involve risks and uncertainties. Among the important additional factors that could cause actual results to differ materially from those forward-looking statements are risks associated with the overall economic environment, changes in anticipated earnings of the company and other factors detailed in the company's filings with the SEC. In addition, the factors underlying Company forecasts are dynamic and subject to change and therefore those forecasts speak only as of the date they are given. The Company does not undertake to update them; however, it may choose from time to time to update them and if it should do so, it will disseminate the updates to the investing public.
GeNOsys Announces Production of Generators : Biotech Finances
GeNOsys Announces Production of Generators
PROVO, Utah--(BUSINESS WIRE)-- GeNOsys, Inc. (OTCBB: GNYS) today announced the building of the first group of production nitric oxide gas generators. It is anticipated that the generators will be assembled and tested over the next few weeks. The Company plans to place this initial group of generators in research laboratories to facilitate the research of nitric oxide gas in the treatment of a number of conditions and diseases, research that has been very difficult due to the current high cost of nitric oxide gas.
"We are looking forward to placing these units in service in the near future to enable an acceleration of medical research utilizing nitric oxide gas," stated Mr. John W.R. Miller, Chairman of the Board. "Making available systems that will generate nitric oxide gas, on demand and at an affordable cost, will be a valuable tool to researchers."
About GeNOsys:
GeNOsys, Inc. (generated nitric oxide systems) is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems. Nitric oxide gas will be one of the medical gases that will be generated along with various combinations of beneficial medical gases suitable for the control of human disease. Distribution will be accelerated through the use of already existing distribution networks that currently sell related respiratory products. For further information, see the Company's Website at: www.genosysusa.com.
This press release may contain forward-looking statements including the Company's beliefs about its business prospects and future results of operations. These statements involve risks and uncertainties. Among the important additional factors that could cause actual results to differ materially from those forward-looking statements are risks associated with the overall economic environment, changes in anticipated earnings of the company and other factors detailed in the company's filings with the SEC. In addition, the factors underlying Company forecasts are dynamic and subject to change and therefore those forecasts speak only as of the date they are given. The Company does not undertake to update them; however, it may choose from time to time to update them and if it should do so, it will disseminate the updates to the investing public.
GeNOsys Announces Production of Generators : Biotech Finances
